Compare CVV & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | ATNM |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 31.7M |
| IPO Year | 2007 | 2013 |
| Metric | CVV | ATNM |
|---|---|---|
| Price | $4.44 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 103.4K | ★ 143.3K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.86 | 14.17 |
| EPS | ★ 1.58 | 0.71 |
| Revenue | ★ $41,128,639.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.80 | ★ $1.65 |
| Revenue Growth | ★ 96.27 | 11.11 |
| 52 Week Low | $2.96 | $0.74 |
| 52 Week High | $9.10 | $1.74 |
| Indicator | CVV | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
CVD Equipment Corp designs, develops, and manufactures a broad range of equipment used to develop and produce materials and coatings for the aerospace, compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as industrial applications, and research. It currently conducts its business through two reportable segments: CVD Equipment, which designs and manufactures chemical vapor deposition, physical vapor transport and thermal process equipment; and SDC, which designs and manufactures ultra-high purity gas and chemical delivery control systems. Its target markets are aerospace & defense and industrial, microelectronics / high power electronics, and EV battery materials / energy storage.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.